Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?
Baron, Frédéric; Nagler, Arnon
2016 • In European Journal of Haematology, 97, p. 215-216
Best allogeneic transplantation approach for AML patients in first CR: is delayed unrelated donor bone marrow transplantation better than immediate unrelated cord blood transplantation?
Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016;127:62–70.
Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Exp Rev Hematol 2016;9:297–314.
Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010;11:653–60.
Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–85.
Schmid C, Labopin M, Socie G, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood 2015;126:2062–9.
